Breaking News Instant updates and real-time market news.

MYL

Mylan

$35.94

-0.9 (-2.44%)

, UA

Under Armour

$38.35

0.57 (1.51%)

10:25
10/10/16
10/10
10:25
10/10/16
10:25

On The Fly: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Mylan (MYL) upgraded to Strong Buy from Market Perform at Raymond James with Elliot WIlbur saying the Department of Justice settlement over EpiPen rebates eliminates a significant overhang on shares enabling the focus to be back on fundamentals. 2. Under Armour (UA) upgraded to Outperform from Market Perform at Wells Fargo with analyst Tom Nikic saying "noise" from the Sports Authority's bankruptcy is fading while distribution expansion could lead to sales re-acceleration over the next 12-18 months. 3. Deere (DE) and AGCO (AGCO) were upgraded to Outperform from Market Perform at Wells Fargo. 4. Dow Chemical (DOW) upgraded to Buy from Neutral at UBS with analyst John Roberts saying the merger with DuPont (DD) could gain regulatory approval and that the stock is "now too cheap to ignore." 5. Exelixis (EXEL) upgraded to Overweight from Neutral at Piper Jaffray with analyst Edward Tenthoff saying the data are "good enough" to file a supplemental new drug application and could drive off-label front-line RCC use. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

MYL

Mylan

$35.94

-0.9 (-2.44%)

UA

Under Armour

$38.35

0.57 (1.51%)

DE

Deere

$88.14

1.84 (2.13%)

AGCO

AGCO

$52.27

2.07 (4.12%)

DOW

Dow Chemical

$53.67

0.68 (1.28%)

EXEL

Exelixis

$12.95

-0.23 (-1.75%)

  • 10

    Oct

  • 10

    Oct

  • 13

    Oct

  • 25

    Oct

  • 26

    Oct

  • 09

    Nov

  • 16

    Nov

  • 28

    Mar

MYL Mylan
$35.94

-0.9 (-2.44%)

10/10/16
WELS
10/10/16
NO CHANGE
WELS
Mylan settlement does not end EpiPen issue, says Wells Fargo
In a research note titled "Forget After Hrs. Quarterbacking - It is Not Back to Normal," Wells Fargo analyst David Maris says Mylan questions still remain after the company's lowered 2016 outlook and $465M Department of Justice settlement. One of Mylan's earnings levers, EpiPen pricing, is now off the table going forward, Maris tells investors in a research note. The analyst disagrees with investors that think the settlement puts the EpiPen pricing issue largely behind the company. The deal with the DOJ addresses only the Centers for Medicare and Medicaid Services portion of the issue, it does nothing to answer the original issue of EpiPen pricing and consumers, Maris contends. He points out that Mylan also disclosed in Friday's regulatory filing, but not in its press release, an SEC investigation by the Division of Enforcement. Maris says he's "not too excited" and doesn't gauge how good the news is by the after-hours share rally of 10%. He believes Mylan is "not back to normal" and keeps a Market Perform rating on the stock with a $43-$45 price target range. The shares are up 12% in pre-market trading to $40.35. Raymond James this morning upgraded Mylan to Strong Buy.
10/10/16
JPMS
10/10/16
NO CHANGE
Target $52
JPMS
Overweight
Mylan settlement, updated guidance a positive, says JPMorgan
JPMorgan analyst Chris Schott views Mylan's $465M settlement with the Department of Justice relating to the potential misclassification of Epipen in the Medicaid Drug Rebate Program as well as its updated 2016 guidance as a positive. The news "removes litigation overhang at a reasonable cost and highlights the diversification of the base business and inexpensive valuation," Schott tells investors in a research note. He keeps an Overweight rating on Mylan with a $52 price target.
10/10/16
RAJA
10/10/16
UPGRADE
Target $57
RAJA
Strong Buy
Mylan upgraded to Strong Buy on EpiPen settlement at Raymond James
As previously reported, Raymond James upgraded Mylan two notches to Strong Buy from Market Perform and established a $57 price target. Analyst Elliot WIlbur said the Department of Justice settlement over EpiPen rebates eliminates a significant overhang on shares enabling the focus to be back on fundamentals. With depressed absolute and relative valuation levels, Wilber sees favorable risk/reward scenarios even in a more tempered earnings growth environment.
10/10/16
UBSW
10/10/16
NO CHANGE
Target $60
UBSW
Buy
UBS remains constructive on Mylan despite governance controversy
UBS analyst Marc Goodman said he remains constructive on Mylan despite the controversy surrounding its corporate governance. Goodman cited the company's ability to execute, its surprise announcement of a EpiPen Medicaid lawsuit settlement and its updated guidance, which was better than feared. Goodman reiterated his Buy rating and lowered his price target to $60 from $66 on Mylan shares.
UA Under Armour
$38.35

0.57 (1.51%)

10/10/16
WELS
10/10/16
UPGRADE
WELS
Outperform
Under Armour upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Tom Nikic upgraded Under Armour to Outperform saying "noise" from the Sports Authority's bankruptcy is fading while distribution expansion could lead to sales reacceleration over the next 12-18 months. The analyst believes Under Armour's growth story is intact heading into 2017 and that its inventory levels are improving. Nikic raised his price target range for the shares to $44-$46 from $38-$42.
10/06/16
ROTH
10/06/16
NO CHANGE
Target $22.5
ROTH
Buy
Under Armour deal should drive MINDBODY platform exposure, says Roth Capital
Roth Capital analyst Darren Aftahi notes that Under Armour (UA) has announced integration of its popular MyFitnessPal application with MINDBODY's (MB) platform. The partnership will enable users to search, book and pay for fitness classes directly on the app, which the analyst believes should be beneficial to MINDBODY's subscribers and its business in general. While it is unclear whether the deal with Under Armour is exclusive, the analyst believes it could open the door for MINDBODY to strike similar deals with other large fitness apparel companies like Nike (NKE) and its Nike+ mobile application. He reiterates a Buy rating and $22.50 price target on MINDBODY's shares.
09/30/16
GUGG
09/30/16
INITIATION
Target $50
GUGG
Buy
Under Armour initiated with a Buy at Guggenheim
Guggenheim analyst Robert Drbul initiated Under Armour with a Buy and a $50 price target as he expects growth in the strong activewear/athletic category to continue and believes a premium multiple is warranted.
09/13/16
09/13/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Chevron (CVX) initiated with an Outperform at BMO Capital. 2. AB InBev (BUD) initiated with a Buy at Jefferies. 3. Altria Group (MO) and Reynolds American (RAI) were initiated with a Buy at Citi while the firm initiated Philip Morris (PM) with a Neutral. 4. Under Armour (UA) initiated with a Neutral at Nomura. 5. Xerox (XRX) initiated with a Buy at SunTrust. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
DE Deere
$88.14

1.84 (2.13%)

09/07/16
09/07/16
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Navistar (NAV) initiated with a Hold at Deutsche Bank. 2. Barrick Gold (ABX) initiated with a Sell at Berenberg while the firm initiated Randgold (GOLD), Kinross Gold (KGC), and Goldcorp (GG) with a Hold. 3. 3. After the close on Tuesday, Deutsche Bank analysts Nicole DeBlase, Saree Boroditsky, and Kevin Marek initiated the U.S. Machinery group with a "cautious view." Oshkosh (OSK), Caterpillar (CAT), and Wabtec (WAB) were initiated with Buy ratings at Deutsche Bank, while the firm initiated Cummins (CMI) and CNH Industrial (CNHI) with Sell ratings. The firm also initiated Deere (DE), AGCO (AGCO), Terex (TEX), PACCAR (PCAR), WABCO (WBC), and United Rentals (URI) with Hold ratings. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/14/16
BARD
09/14/16
NO CHANGE
Target $86
BARD
Neutral
Baird remains cautious on Deere after survey of ag equipment dealers
Baird analyst Mig Dobre remains cautious on Deere shares following a "stubbornly weak" agricultural equipment orders survey of dealers. The report pointed to a third year of equipment early order program declines, with declines only marginally improved from last year. Dobre feels the potential magnitude of decline in 2017 could surprise negatively. Dobre maintained his Neutral rating and lowered his price target to $86 from $90 on Deere shares.
10/10/16
WELS
10/10/16
UPGRADE
WELS
Outperform
Deere upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Andrew Casey upgraded Deere to Outperform after hosting investor meetings with management. After three years of global farm equipment demand decline, the market may be bottoming and turning positive, Casey tells investors in a research note. Deere is seeing improvement in Brazil, parts of Europe, Ukraine, Russia, India and other regions, the analyst contends. He raised his price target range for the shares to $100-$103 from $85-$88.
10/10/16
WELS
10/10/16
UPGRADE
WELS
Outperform
AGCO upgraded to Outperform from Market Perform at Wells Fargo
Wells Fargo analyst Andrew Casey upgraded AGCO (AGCO) to Outperform saying that after three years of demand decline, the company will benefit from an anticipated bottoming in global farm equipment demand. More favorable indications in Brazil and Europe should benefit approximately 70% of the company's revenue mix, Casey tells investors in a research note. He raised his price target range for the shares to $60-$63 from $46-$49. The analyst this morning also upgraded Deere (DE) to Outperform.
AGCO AGCO
$52.27

2.07 (4.12%)

09/06/16
DBAB
09/06/16
INITIATION
Target $54
DBAB
Hold
AGCO initiated with a Hold at Deutsche Bank
Target $54.
07/25/16
PIPR
07/25/16
DOWNGRADE
Target $5
PIPR
Underweight
CNH Industrial downgraded to Underweight from Neutral at Piper Jaffray
Piper Jaffray analyst Brett Wong downgraded CNH Industrial (CNHI) to Underweight on expectations the current agriculture downturn is going to persist in 2017 for a fourth consecutive year. Growing conditions have been "extremely favorable," making another large U.S. corn crop this year very likely, Wong tells investors in a research note. He expects grain prices to remain weak and lowered his price target for CNH shares to $5 from $7. Wong this morning also downgraded Deere (DE) and AGCO (AGCO) to Underweight.
DOW Dow Chemical
$53.67

0.68 (1.28%)

10/03/16
SBSH
10/03/16
UPGRADE
SBSH
Buy
Dow Chemical upgraded to Buy from Neutral at Citi
Citi analyst P.J. Juvekar upgraded Dow Chemical (DOW) to Buy from Hold citing the opportunity presented by the proposed merger with DuPont (DD). The analyst also upgraded DuPont to Buy from Hold this morning.
10/10/16
UBSW
10/10/16
UPGRADE
Target $62
UBSW
Buy
Dow Chemical upgraded to Buy from Neutral at UBS
UBS analyst John Roberts upgraded Dow Chemical (DOW) to Buy saying the merger with DuPont (DD) could gain regulatory approval and that the stock is "now too cheap to ignore." The analyst sees $3B in potential cost savings and expects improving cash flow. Roberts raised his price target for the shares to $62 from $53.
10/03/16
10/03/16
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Dow Chemical (DOW) and DuPont (DD) were upgraded to Buy from Neutral at Citi with analyst P.J. Juvekar citing he opportunity presented by the proposed merger. 2. Freeport McMoRan (FCX), Barrick Gold (ABX), and Pan American Silver (PAAS) were upgraded to Buy from Hold at Deutsche Bank. 3. LogMeln (LOGM) upgraded to Overweight from Equal Weight at Barclays with analyst Raimo Lenschow saying the pending merger with Citrix's (CTXS) divested GoTo assets creates a "great new opportunity." 4. Halliburton (HAL) upgraded to Buy from Hold at Societe General. 5. Coty (COTY) upgraded to Buy from Neutral at BofA/Merrill with analyst Olivia Tong saying she believes Coty is at the beginning of a potential transformation with the pending closure of the P&G Beauty deal this week that could bring increased scale as well as a more targeted operational structure. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/03/16
SBSH
10/03/16
UPGRADE
SBSH
Buy
Citi upgrades Dow and DuPont, says DowDuPont could be 'stock to own' in 2017
As previously reported, Citi analyst P.J. Juvekar upgraded shares of both Dow Chemical (DOW) and DuPont (DD), each to Buy from Hold, citing their "massive" cost-cutting opportunity after their proposed merger goes through as well as the potential for upside to the companies' stated $3B synergy target. If their deal gets completed, the combined Dow-DuPont would "be the stock to own in 2017," said Juvekar, who raised the firm's price target on DuPont shares to $76 from $72 and increased the target for Dow shares to $59 from $55.
EXEL Exelixis
$12.95

-0.23 (-1.75%)

09/28/16
LEER
09/28/16
NO CHANGE
LEER
Outperform
Exelixis selloff based on ESMO abstracts overdone, says Leerink
Leerink analyst Michael Schmidt believes Exelixis' selloff following the publication of ESMO poster abstracts is overdone. The analyst notes that abstract includes updated data from a Phase Ib trial evaluating the combination of axitinib with pembrolizumab and appears to have sparked competitive concerns for Exelixis. However, he believes it is highly premature to draw conclusions at this point on the company's Cabometyx' market opportunity or potential in Renal Cell Carcinoma. Schmidt reiterates an Outperform rating on the shares. In afternoon trading, Exelixis' stock has dropped over 15% to $13.12 per share.
10/10/16
LEER
10/10/16
NO CHANGE
LEER
Outperform
Leerink says ESMO raises confidence in potential label expansions at Exelixis
Following several oral and poster presentations this weekend at the ESMO cancer meeting, Leerink analyst Michael Schmidt said he has greater confidence regarding several potential label expansion opportunities for Exelixis' two products, Cabometyx and Cotellic. Cabometyx is "very well positioned" to capture significant market share and consensus expectations for Cotellic are only modest, believes Schmidt, who keeps an Outperform rating on Exelixis shares.
10/10/16
PIPR
10/10/16
UPGRADE
PIPR
Overweight
Exelixis upgraded to Overweight from Neutral at Piper Jaffray
10/10/16
PIPR
10/10/16
UPGRADE
Target $21
PIPR
Overweight
Exelixis upgraded to Overweight after trial success at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff upgraded Exelixis to Overweight from Neutral after the company reported Phase II CABOSUN data in 157 front-line metastatic Renal Cell Carcinoma patients. The data are "good enough" to file a supplemental new drug application and could drive off-label front-line RCC use, Tenthoff tells investors in a research note. The analyst raised his price target for the shares to $21 from $8.

TODAY'S FREE FLY STORIES

OXFD

Oxford Immunotec

$15.34

0.2 (1.32%)

16:45
06/22/17
06/22
16:45
06/22/17
16:45
Hot Stocks
Oxford Immunotec announces reimbursement decision for T-SPOT test in France »

Oxford Immunotec Global…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVH

Evolent Health

$25.90

-0.85 (-3.18%)

16:40
06/22/17
06/22
16:40
06/22/17
16:40
Syndicate
Evolent Health files to sell 4.5M shares of Class A common stock for holders »

Goldman Sachs & Co.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IDRA

Idera Pharmaceuticals

$1.73

0.02 (1.17%)

16:34
06/22/17
06/22
16:34
06/22/17
16:34
Hot Stocks
Idera announces FDA orphan drug designation for IMO-2125 for melanoma treatment »

Idera Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:33
06/22/17
06/22
16:33
06/22/17
16:33
General news
Fed Balance Sheet Level data reported »

Week of 6/21 Fed Balance…

16:33
06/22/17
06/22
16:33
06/22/17
16:33
General news
Money Supply M2 Weekly Change data reported »

Week of 6/12 Money Supply…

MGM

MGM Resorts

$33.25

0.29 (0.88%)

16:33
06/22/17
06/22
16:33
06/22/17
16:33
Hot Stocks
Breaking Hot Stocks news story on MGM Resorts »

Soroban Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$219.77

-2.72 (-1.22%)

, BAC

Bank of America

$22.93

-0.2 (-0.86%)

16:32
06/22/17
06/22
16:32
06/22/17
16:32
Hot Stocks
All 34 banks exceed minimum requirements of Fed Stress Test »

Publicly traded banks…

GS

Goldman Sachs

$219.77

-2.72 (-1.22%)

BAC

Bank of America

$22.93

-0.2 (-0.86%)

C

Citi

$63.62

-0.21 (-0.33%)

WFC

Wells Fargo

$52.49

-0.49 (-0.92%)

JPM

JPMorgan

$87.02

-0.1 (-0.11%)

MS

Morgan Stanley

$44.61

-0.3 (-0.67%)

USB

U.S. Bancorp

$51.30

-0.7 (-1.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 14

    Jul

  • 14

    Jul

  • 18

    Jul

  • 19

    Jul

  • 25

    Jul

  • 12

    Oct

  • 12

    Oct

  • 17

    Oct

  • 18

    Oct

  • 15

    Jan

  • 17

    Jan

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

16:30
06/22/17
06/22
16:30
06/22/17
16:30
Options
Preliminary option volume of 14.6M today »

Preliminary option volume…

GOOG

Alphabet

$957.09

-2.36 (-0.25%)

, GOOGL

Alphabet Class A

$976.62

-1.97 (-0.20%)

16:27
06/22/17
06/22
16:27
06/22/17
16:27
Hot Stocks
YouTube developing 'VR180' video format, says team working with camera makers »

Alphabet's (GOOG)…

GOOG

Alphabet

$957.09

-2.36 (-0.25%)

GOOGL

Alphabet Class A

$976.62

-1.97 (-0.20%)

LNVGY

Lenovo

$12.85

0.059 (0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

BBBY

Bed Bath & Beyond

$33.73

0.07 (0.21%)

16:25
06/22/17
06/22
16:25
06/22/17
16:25
Hot Stocks
Breaking Hot Stocks news story on Bed Bath & Beyond »

Bed Bath & Beyond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 29

    Jun

NAT

Nordic American Tankers

$6.00

-0.02 (-0.33%)

16:25
06/22/17
06/22
16:25
06/22/17
16:25
Syndicate
Breaking Syndicate news story on Nordic American Tankers »

Nordic American Tankers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JONE

Jones Energy

16:25
06/22/17
06/22
16:25
06/22/17
16:25
Hot Stocks
Jones Energy exits Arkoma Basin with non-core asset sales »

Jones Energy announced …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

GBL

GAMCO Investors

$29.89

0.27 (0.91%)

, CIR

CIRCOR

$58.20

2.98 (5.40%)

16:24
06/22/17
06/22
16:24
06/22/17
16:24
Hot Stocks
Breaking Hot Stocks news story on GAMCO Investors, CIRCOR »

Gabelli reports 15.94%…

GBL

GAMCO Investors

$29.89

0.27 (0.91%)

CIR

CIRCOR

$58.20

2.98 (5.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

BBBY

Bed Bath & Beyond

$33.74

0.08 (0.24%)

16:23
06/22/17
06/22
16:23
06/22/17
16:23
Hot Stocks
Bed Bath & Beyond says saw increased 'softness in transactions in stores' in Q1 »

At this time, Bed Bath…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 29

    Jun

CPE

Callon Petroleum

$9.69

-0.06 (-0.62%)

16:21
06/22/17
06/22
16:21
06/22/17
16:21
Hot Stocks
Callon Petroleum appoints Correne S. Loeffler as Interim CFO »

Callon Petroleum has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 14

    Nov

BBBY

Bed Bath & Beyond

$33.74

0.08 (0.24%)

16:21
06/22/17
06/22
16:21
06/22/17
16:21
Hot Stocks
Bed Bath & Beyond repurchased approximately $127M of common stock in Q1 »

During the fiscal 2017…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 29

    Jun

SGH

Smart Global

$16.20

0.45 (2.86%)

16:20
06/22/17
06/22
16:20
06/22/17
16:20
Earnings
Smart Global sees Q4 EPS 62c-66c, consensus 57c »

Sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

SNX

SYNNEX

$121.84

1.51 (1.25%)

16:19
06/22/17
06/22
16:19
06/22/17
16:19
Hot Stocks
SYNNEX approves $300M share repurchase program »

SYNNEX has approved an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

AAL

American Airlines

$48.97

0.54 (1.12%)

, HCA

HCA Holdings

$86.14

2.09 (2.49%)

16:19
06/22/17
06/22
16:19
06/22/17
16:19
General news
On The Fly: Top stock stories for Thursday »

Stocks began the session…

AAL

American Airlines

$48.97

0.54 (1.12%)

HCA

HCA Holdings

$86.14

2.09 (2.49%)

PLNT

Planet Fitness

$23.95

0.38 (1.61%)

THC

Tenet

$18.89

1.21 (6.84%)

UNH

UnitedHealth

$186.50

1.58 (0.85%)

HUM

Humana

$237.00

0.79 (0.33%)

AET

Aetna

$152.98

0.88 (0.58%)

RAD

Rite Aid

$3.08

-0.11 (-3.45%)

WBA

Walgreens Boots Alliance

$76.37

-1.75 (-2.24%)

ORCL

Oracle

$50.30

3.97 (8.57%)

SPLS

Staples

$9.20

0.54 (6.24%)

JWN

Nordstrom

$47.48

1.4 (3.04%)

WB

Weibo

$72.25

-4.71 (-6.12%)

SCS

Steelcase

$14.10

-2.2 (-13.50%)

ACN

Accenture

$122.08

-5.03 (-3.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 22

    Jun

  • 22

    Jun

  • 26

    Jun

  • 28

    Jun

  • 29

    Jun

  • 07

    Jul

  • 18

    Jul

  • 23

    Aug

BBBY

Bed Bath & Beyond

$33.74

0.08 (0.24%)

16:19
06/22/17
06/22
16:19
06/22/17
16:19
Hot Stocks
Bed Bath & Beyond reports Q1 SSS from customer-facing digital channels up 20%+ »

Comparable sales in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 29

    Jun

SNX

SYNNEX

$121.96

1.62 (1.35%)

16:18
06/22/17
06/22
16:18
06/22/17
16:18
Earnings
SYNNEX sees Q3 non-GAAP EPS $1.94-$2.02, consensus $1.92 »

Sees Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

BBBY

Bed Bath & Beyond

$33.74

0.08 (0.24%)

16:18
06/22/17
06/22
16:18
06/22/17
16:18
Earnings
Bed Bath & Beyond reports Q1 EPS 53c, consensus 66c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 29

    Jun

SNX

SYNNEX

$121.84

1.51 (1.25%)

16:17
06/22/17
06/22
16:17
06/22/17
16:17
Earnings
SYNNEX reports Q2 non-GAAP EPS $2.08, consensus $1.79 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

$NSD

NASDAQ Market Internals

16:17
06/22/17
06/22
16:17
06/22/17
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBBY

Bed Bath & Beyond

$33.74

0.08 (0.24%)

16:16
06/22/17
06/22
16:16
06/22/17
16:16
Hot Stocks
Breaking Hot Stocks news story on Bed Bath & Beyond »

Bed Bath & Beyond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 29

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.